{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:57:40Z","timestamp":1773975460975,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"Abstract<\/jats:title>Introduction<\/jats:title>Obsessive\u2010compulsive disorder (OCD) is marked by a high rate of treatment resistance. Patients are often left trialing medications within multiple drug classes with little response, causing heterogeneity to emerge in prescribing patterns. This analysis seeks to investigate the selection and dosing of the pharmacotherapy utilized, to portray an overview of prescribing trends in the United States.<\/jats:p><\/jats:sec>Methods<\/jats:title>This retrospective, single center, review of electronic medical records investigated the pharmacotherapy utilization of patients with a primary diagnosis of OCD. Two hundred and ninety\u2010five patients who received OCD treatment at an urban, academic medical center were included in the study. Patients were included in the review if they were at least eighteen years of age and were assigned a diagnosis of OCD according to DSM\u20105 criteria.<\/jats:p><\/jats:sec>Results<\/jats:title>Psychotropic pharmacotherapy was integrated into the care of 93% of patients. Selective serotonin reuptake inhibitors were the most utilized medication class at 85% followed by benzodiazepines (47%) and second\u2010generation antipsychotics (37%). Tricyclic antidepressants and first\u2010generation antipsychotics were the two medication classes utilized the least at 13% and 2% respectively. Additionally, mood stabilizers and serotonin\u2010norepinephrine reuptake inhibitors were utilized at rates of 8% and 16%, respectively.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Evidence\u2010based treatment guidelines are being followed with varying augmentation strategies widely prevalent, thus displaying the heterogeneity in treating OCD. A high rate of benzodiazepine utilization highlights a practice trend with potential ties to clinical factors, such as the latency to treatment effect of other first\u2010line pharmacotherapies. Future prospective studies are required to determine the cultural, pharmacoeconomic and pharmacogenomic factors that contribute to the variation in prescribing practices and whether these variations influence treatment outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2900","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T12:13:00Z","timestamp":1715429580000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescribing patterns in patients with obsessive\u2010compulsive disorder: Retrospective, single\u2010center study"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8330-068X","authenticated-orcid":false,"given":"Joshua","family":"Knebel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice University of the Incarnate Word San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Lindsey Hedgepeth","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of North Carolina Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. (2013).Diagnostic and statistical manual of mental disorders(5th ed.).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_10_3_1","volume-title":"Treatment of patients with obsessive\u2013compulsive disorder [online]","author":"A.P.A","year":"2007"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114525674"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802465807"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v67n0611"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2009.50"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2541"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12016"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2006.02.013"},{"key":"e_1_2_10_11_1","unstructured":"Drug Enforcement Administration. (2023).Benzodiazepines (street names: Benzos downers nerve pills tranks).https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/benzo.pdf"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s83130"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14r09758"},{"key":"e_1_2_10_14_1","first-page":"1099","volume-title":"Pharmacotherapy: A pathophysiologic approach","author":"Kirkwood C. K.","year":"2017"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008141.pub2"},{"key":"e_1_2_10_16_1","first-page":"325","volume-title":"The global burden of diseases: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020","author":"Murray C.","year":"1996"},{"key":"e_1_2_10_17_1","volume-title":"Obsessive\u2013compulsive disorder: Core interventions in the treatment of obsessive\u2013compulsive disorder and body dysmorphic disorder. [Online]","author":"N.I.C.E","year":"2005"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.04.035"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100447.2004.00502.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.703701"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215\u20100366(16)30069\u20104"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000100"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s178207"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113517955"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2022.152352"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T09:39:58Z","timestamp":1731836398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/hup.2900"],"URL":"https:\/\/doi.org\/10.1002\/hup.2900","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]},"assertion":[{"value":"2023-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2900"}}